This is a paragraph. Click here to edit the text. It's easy. Just click here to add your own content and make changes to it.This is a paragraph. Click here to edit the text. It's easy. Just click here to add your own content and make changes to it.The Indian Council for Medical Research (ICMR) on Saturday announced a research collaboration with Hyderabad-based Bharat Biotech International Ltd (BBIL) to develop a COVID-19 vaccine.
The ICMR said in a statement that it had transferred the virus strain isolated at the National Institute of Virology, Pune (an ICMR institute) to BBIL.
“...Work on vaccine development has been initiated between the two partners. ICMR-NIV will provide continuous support to BBIL for vaccine development. ICMR and BBIL will seek fast-track approvals to expedite vaccine development, subsequent animal studies and clinical evaluation of the candidate vaccine, which will be fully indigenous to India,” the ICMR statement said.
No further details were available on whether any pre-clinical studies were done or the basis for which this appeared to be a promising step forward for successfully developing a vaccine.
Chairman and Managing Director of Bharat Biotech Dr. Krishna Ella said in a statement: “We are very proud to participate in this project of national importance with ICMR and NIV. We will do everything to make this program successful in our nation endeavour to combat COVID-19 pandemic.”